Can Metformin Help with Weight Loss? Here’s What to Know

Metformin has been around for decades—but recently, it’s been getting attention for more than just blood sugar control. At Alan Health, we offer low-dose Metformin as part of our weight management toolkit, especially for people experiencing slow progress, insulin resistance, or hormonal shifts.

If you’ve hit a plateau or feel like your body’s working against you, here’s what to know about Metformin—and how it might help.

What Is Metformin?

Metformin is a well-established, FDA-approved medication traditionally used to manage type 2 diabetes. It works by:

• Improving how your body responds to insulin
• Reducing glucose production in the liver
• Helping cells use sugar more efficiently

At lower doses, it’s now being explored off-label for weight loss and metabolic support—even in people who don’t have diabetes.

How Metformin Supports Weight Loss

Metformin isn’t a stimulant or appetite suppressant—but it supports weight loss by helping your metabolism work more effectively.

Here’s how:

• Improves Insulin Sensitivity: Insulin is a hormone that tells your body how to use energy. When your body becomes less responsive to it (a condition called insulin resistance), it can store more fat—especially around the midsection. Metformin helps reverse this.
  ‍
• Reduces Cravings & Appetite: While not designed as an appetite suppressant, many people report feeling fewer cravings—particularly for carbs and sugar—while on Metformin.
  ‍
• Supports Stable Blood Sugar: Fewer highs and lows can lead to more balanced energy, better moods, and less emotional or reactive eating.
  ‍
• Complements GLP-1 Medications: For those already taking Semaglutide or Tirzepatide, Metformin can offer additional metabolic support—especially if weight loss has stalled.

What to Expect

Metformin is generally taken once or twice daily, starting at a low dose to support tolerance. It’s most effective when paired with other healthy habits like:

• A fiber- and protein-rich diet
• Regular movement, including strength training
• Consistent sleep and stress management

It’s not a “quick fix”—but over time, it can help rebalance your metabolism, support fat loss, and reduce insulin-related roadblocks.

Who Might Benefit from Metformin?

Metformin may be a good fit if you:

• Feel like you’re doing everything “right” but progress is slow
• Struggle with midsection weight, cravings, or energy dips
• Have a history of insulin resistance, PCOS, or prediabetes
• Are already on GLP-1 medication but hitting a plateau

Your Alan Health provider can evaluate whether Metformin is appropriate based on your goals, labs (if applicable), and how your body’s responding to treatment.

A Science-Backed Way to Support Your Goals

If you're looking for a gentle, non-stimulant option to support your metabolism and overcome a plateau, Metformin may be worth considering.

It’s not about shortcuts—it’s about working with your body’s chemistry to make sustainable progress.

👉 See if Metformin is right for you →

{{metformin}}

Resources

Apovian et al. (2019) published clinical practice guidelines in The Journal of Clinical Endocrinology & Metabolism outlining the pharmacological management of obesity, including the off-label use of medications like Metformin to support weight loss and metabolic health. https://doi.org/10.1210/jc.2014-3415

Heck et al. (2000) explored the role of Metformin in managing polycystic ovary syndrome (PCOS), noting its impact on insulin resistance, weight, and hormonal balance in Annals of Pharmacotherapy. https://doi.org/10.1345/aph.19367

A systematic review and meta-analysis by Seifarth et al. (2013) in Diabetes, Obesity and Metabolism found that Metformin contributed to modest but meaningful weight loss in overweight and obese patients without diabetes. https://doi.org/10.1111/dom.12062

Viollet et al. (2012) offered a comprehensive overview of the cellular and molecular mechanisms of Metformin in Clinical Science, reinforcing its role in glucose regulation, fat metabolism, and insulin sensitivity. https://doi.org/10.1042/CS20110386

‍